🇺🇸 GH — Guardant Health, Inc.

Salud Compra fuerte
← Volver

Precio actual

170,73 USD

Máx. histórico

187,22

28 días

Caída desde máximo

-8,81%

Rango 52 semanas

74,55 – 191,05

Variación hoy

-4,51%

Cierre anterior

178,80

Rango de hoy

167,94 – 180,05

Volumen hoy

2.389.042

Peor caída histórica

-91,03%

12/02/2021 → 19/04/2024

Recuperado en 881 días

Volatilidad anualizada ⓘ

67,36%

Información
Nombre completo
Guardant Health, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Diagnostics & Research
Empleados
2.490
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
202,24 USD (puede no estar actualizado)
Primera cotización
04/10/2018
Precio actualizado
hace 23 horas
Sobre la empresa

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
31/10/2018 34,41 35,89 33,05 33,48 -1,73% 8,25% 340.000
30/10/2018 31,99 34,24 31,01 34,07 +4,54% 10,10% 340.900
29/10/2018 36,00 37,00 31,52 32,59 -6,86% 15,22% 516.300
26/10/2018 34,82 35,72 33,60 34,99 -0,43% 6,09% 329.600
25/10/2018 34,55 35,24 32,18 35,14 +1,24% 8,86% 379.500
24/10/2018 34,06 37,84 34,06 34,71 +0,67% 11,10% 308.500
23/10/2018 36,46 36,50 33,43 34,48 -7,83% 8,42% 502.200
22/10/2018 36,01 38,37 35,52 37,41 +4,53% 7,91% 363.600
19/10/2018 40,51 43,25 35,38 35,79 -10,77% 19,43% 774.000
18/10/2018 40,53 44,25 37,75 40,11 -1,52% 16,04% 1.296.200
17/10/2018 38,49 43,80 37,77 40,73 +7,98% 15,67% 935.900
16/10/2018 33,75 37,90 33,75 37,72 +13,04% 12,30% 690.400
15/10/2018 33,88 34,34 32,72 33,37 -0,63% 4,78% 471.300
12/10/2018 32,00 34,42 31,98 33,58 +6,27% 7,63% 483.800
11/10/2018 31,58 32,40 30,85 31,60 +2,20% 4,91% 478.500
10/10/2018 31,51 32,68 30,66 30,92 -1,87% 6,41% 1.297.400
09/10/2018 29,63 32,56 28,73 31,51 +6,63% 12,93% 719.600
08/10/2018 29,78 30,41 28,52 29,55 +1,20% 6,35% 1.061.800
05/10/2018 31,89 32,69 28,75 29,20 -9,32% 12,35% 1.703.300
04/10/2018 27,75 35,50 27,04 32,20 — 30,49% 10.336.300